Ben-Baruch Adit
Cancer Biology Research Center, Department of Cell Research and Immunology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Clin Exp Metastasis. 2008;25(4):345-56. doi: 10.1007/s10585-007-9097-3. Epub 2007 Sep 21.
Cancer metastasis results from a non-random process, in which organ selectivity by the tumor cells is largely determined by factors that are expressed at the remote organs that eventually turn into preferred sites of metastasis formation. These factors support the consecutive steps required for metastasis formation, including tumor cell adhesion to microvessel walls, extravasation into target tissue and migration. Of the different components that regulate organ selectivity, instrumental roles were recently attributed to chemokines and their receptors. The present review presents the rationale standing behind the first studies looking at the potential involvement of chemokine-related components in organ selectivity. Based on these studies and many others that followed, the current paradigm is that chemokines that are expressed at specific organs determine to large extent organ specificity by promoting tumor cell adhesion to microvessel walls, by facilitating processes of extravasation into the target tissue and by inducing tumor cell migration. Moreover, chemokines can possibly support additional steps that are required for "successful" establishment of metastases, such as tumor cell proliferation and survival. The review focuses on the CXCL12-CXCR4 pair as the role model in our current understanding of chemokine involvement in organ selectivity. This review also describes the prominent roles played by CCR7 and its corresponding chemokine ligands (CCL21, CCL19) in lymph node metastasis, and of the CCR10-CCL27 axis in melanoma skin survival and metastasis. Overall, the present discussion describes chemokines as important constituents of the tumor microenvironment at metastatic sites, dictating directionality of chemokine receptor-expressing tumor cells, facilitating their adhesion and extravasation, and eventually contributing to organ selectivity.
癌症转移是一个非随机过程,在此过程中,肿瘤细胞对器官的选择性很大程度上由远处器官表达的因素决定,这些远处器官最终会成为转移灶形成的优先部位。这些因素支持转移形成所需的连续步骤,包括肿瘤细胞与微血管壁的黏附、向靶组织的外渗和迁移。在调节器官选择性的不同成分中,趋化因子及其受体最近被认为发挥了重要作用。本综述阐述了首批研究趋化因子相关成分在器官选择性中潜在作用的研究背后的基本原理。基于这些研究以及随后的许多其他研究,目前的范式是,特定器官表达的趋化因子通过促进肿瘤细胞与微血管壁的黏附、促进向靶组织的外渗过程以及诱导肿瘤细胞迁移,在很大程度上决定了器官特异性。此外,趋化因子可能支持转移“成功”建立所需的其他步骤,如肿瘤细胞增殖和存活。本综述重点关注CXCL12 - CXCR4这一对因子,将其作为我们目前对趋化因子参与器官选择性理解的典范。本综述还描述了CCR7及其相应趋化因子配体(CCL21、CCL19)在淋巴结转移中的突出作用,以及CCR10 - CCL27轴在黑色素瘤皮肤存活和转移中的作用。总体而言,本讨论将趋化因子描述为转移部位肿瘤微环境的重要组成部分,决定表达趋化因子受体的肿瘤细胞的方向性,促进其黏附和外渗,并最终促成器官选择性。